CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) shares rose 8% to 0.99p after the AIM-listed circulating tumour cell specialist announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease.
Active Energy says Ghummud has been fully energised ahead of schedule
Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) shares were up 11% on Monday, to 0.11p, after the firm told investors that its Ghummud site in the UAE has been fully energised ahead of schedule, potentially pulling forward revenue as the company pushes to build out a digital infrastructure platform around acquired grid connections. The AIM-listed group said modular digital infrastructure deployment is already underway at the site and that operations are now expected to begin materially sooner than the previously indicated 10-12 week timeline.
HeLIX Exploration boosted by new US Air Force hydrogen venture
HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) has been selected by Renaissance Philanthropy's Chimaera Fund to join a US Air Force-backed demonstration programme, giving the AIM-listed gas explorer a foothold in a project tied to military energy resilience and highlighting a possible second strategic use for its Montana geology. The group was chosen from nearly 30 respondents to a request for information aimed at finding partners with relevant well infrastructure, hydrogen-related subsurface data and active exploration programmes near key Air Force bases.
Poolbeg Pharma wins UK regulatory clearance for cancer immunotherapy trial
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has received clinical trial authorisation from the UK Medicines and Healthcare products Regulatory Agency for its TOPICAL trial, with interim data expected this summer. The trial is investigating POLB 001, which is being developed as a potential first-approved preventative therapy for cytokine release syndrome (CRS), a serious immune reaction triggered by cancer immunotherapies, including CAR T-cell therapies and bispecific antibodies.
Seeing Machines is monitoring systems after cyberthreat but says its found no evidence of breach
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z) told investors it has so far found no evidence of unauthorised access to its systems or data, after investigating an alleged cyber threat flagged to the company around 10 days ago. The AIM-listed transport safety technology group said a third party had named it online alongside claims that some company data had been accessed.
Impax Asset Management drops as outflows prompt downgrade
Impax Asset Management (AIM:IPX, FRA:LW4) shares dropped in Friday morning's deals, losing 21% to 98.68p, as the firm reported assets under management fell 8% over its fiscal second quarter to £22.3 billion, as continued client redemptions prompted the AIM-listed specialist investor to guide for lower full-year revenue. Net outflows totalled £2.01 billion in the three months to 31 March 2026, driven principally by listed equities, while performance, market movements and foreign exchange added just £83 million.
Union Jack Oil to spud Crossroads well in mid-April
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) has announced that the Crossroads well in southern Oklahoma is set to be spudded on or around 16 April, giving investors a near-term drilling catalyst on a project where the company already has its funding in place. The AIM-listed group holds a 43% interest in Crossroads, with Reach Oil and Gas acting as operator, and, Union Jack said its share of drilling costs has already been funded, de-risking the immediate cash call ahead of operations.
Cavendish is bullish on 88 Energy as its advancing latest Alaska opportunity
Cavendish sees very substantial upside for 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) after the AIM-listed explorer secured access to a 3D seismic dataset over its Kad River East acreage in Alaska, with the broker reiterating a Buy rating and 19.8p target price (compared to the current price of 1.5p per share). The stockbroker, in a note, highlighted that the firm's newly licensed Kad River 3D survey covers the entirety of the recently acquired leases and strengthens the case for an active, multi-reservoir petroleum system already indicated by legacy 2D seismic and historic well data.
Sorted slump on plan to sell business for £1 and become cash shell
Sorted Group Holdings PLC (AIM:SORT) saw its share price halve to 10p after it unveiled plans to dispose of its main operating business for £1 and become an AIM cash shell, just two years after its arrival via reverse takeover. The AIM-listed software group said it intends to sell Sorted Group Ltd for a nominal consideration, subject to shareholder approval later this month.
Shares slide after Mkango Resources completes £12.5m fundraise, but oversubscription signals longer-term confidence
The AIM-listed rare earths company upsized its placing after strong demand, though shares fell back on dilution concerns. Shares in Mkango Resources Ltd (AIM:MKA, TSX-V:MKA, OTC:MKNGF), the rare earths developer, fell 13% to 33.6p on Wednesday despite the company completing a fundraise that was significantly oversubscribed and upsized from its original £10 million target to £12.5 million.
Poolbeg Pharma shares rise 10% as Australian patent grant bolsters POLB 001 commercial appeal
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF)shares rose as much as 10% in Tuesday morning trading after the AIM-listed biopharmaceutical company secured its first national patent grant for POLB 001. This is the drug developer's lead candidate for preventing a serious side effect of cancer immunotherapy.
Record North Slope lease sale by supermajors shines fresh light on 88 Energy's Alaskan ambitions
ExxonMobil, ConocoPhillips, Repsol and Shell have just competed at the most successful lease sale ever held in Alaska's National Petroleum Reserve. The timing could hardly be better for 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), the AIM-listed explorer advancing plans to drill one of the North Slope's most promising untested prospects.
